Статті в журналах з теми "PI3K TARGET"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "PI3K TARGET".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Diacovo, Thomas, Dosh Whye, Evgeni Efimenko, Jianchung Chen, Valeria Tosello, Kim De Keersmaecker, Adam Kashishian та ін. "Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival". Blood 120, № 21 (16 листопада 2012): 1492. http://dx.doi.org/10.1182/blood.v120.21.1492.1492.
Повний текст джерелаBorsari, Chiara, and Matthias P. Wymann. "Targeting Phosphoinositide 3-Kinase – Five Decades of Chemical Space Exploration." CHIMIA 75, no. 12 (December 9, 2021): 1037. http://dx.doi.org/10.2533/chimia.2021.1037.
Повний текст джерелаBarberis, Laura, та Emilio Hirsch. "Targeting phosphoinositide 3-kinase γ to fight inflammation and more". Thrombosis and Haemostasis 99, № 02 (2008): 279–85. http://dx.doi.org/10.1160/th07-10-0632.
Повний текст джерелаMiller, Michelle, Philip Thompson, and Sandra Gabelli. "Structural Determinants of Isoform Selectivity in PI3K Inhibitors." Biomolecules 9, no. 3 (February 26, 2019): 82. http://dx.doi.org/10.3390/biom9030082.
Повний текст джерелаMercurio, Laura, Martina Morelli, Claudia Scarponi, Giovanni Luca Scaglione, Sabatino Pallotta, Cristina Albanesi та Stefania Madonna. "PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis". Cells 10, № 10 (2 жовтня 2021): 2636. http://dx.doi.org/10.3390/cells10102636.
Повний текст джерелаLaurent, Pierre-Alexandre, Cédric Garcia, Marie-Pierre Gratacap, Bart Vanhaesebroeck, Pierre Sié, Bernard Payrastre та Anne-Dominique Terrisse. "The class I phosphoinositide 3-kinases α and β control antiphospholipid antibodies-induced platelet activation". Thrombosis and Haemostasis 115, № 06 (2016): 1138–46. http://dx.doi.org/10.1160/th15-08-0661.
Повний текст джерелаKuracha, Murali R., Venkatesh Govindarajan, Brian W. Loggie, Martin Tobi, and Benita L. McVicker. "Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells." International Journal of Molecular Sciences 24, no. 15 (August 2, 2023): 12331. http://dx.doi.org/10.3390/ijms241512331.
Повний текст джерелаXenou, Lydia, та Evangelia A. Papakonstanti. "p110δ PI3K as a therapeutic target of solid tumours". Clinical Science 134, № 12 (червень 2020): 1377–97. http://dx.doi.org/10.1042/cs20190772.
Повний текст джерелаMaffei, Angelo, Giuseppe Lembo, and Daniela Carnevale. "PI3Kinases in Diabetes Mellitus and Its Related Complications." International Journal of Molecular Sciences 19, no. 12 (December 18, 2018): 4098. http://dx.doi.org/10.3390/ijms19124098.
Повний текст джерелаChen, Shiyi, Wenkang Huang, Xiaoyu Li, Lijuan Gao, and Yiping Ye. "Identifying Active Compounds and Mechanisms of Citrus changshan-Huyou Y. B. Chang against URTIs-Associated Inflammation by Network Pharmacology in Combination with Molecular Docking." Evidence-Based Complementary and Alternative Medicine 2022 (July 13, 2022): 1–10. http://dx.doi.org/10.1155/2022/2156157.
Повний текст джерелаHutter, Grit, Yvonne Zimmermann, Anna-Katharina Zoellner, Philip Irrgang, Oliver Weigert, Wolfgang Hiddemann, and Martin Dreyling. "Combination of PI3K and PDPK1 Inhibitors Is Highly Effective in Mantle Cell Lymphoma." Blood 124, no. 21 (December 6, 2014): 3123. http://dx.doi.org/10.1182/blood.v124.21.3123.3123.
Повний текст джерелаCourtney, Kevin D., Ryan B. Corcoran, and Jeffrey A. Engelman. "The PI3K Pathway As Drug Target in Human Cancer." Journal of Clinical Oncology 28, no. 6 (February 20, 2010): 1075–83. http://dx.doi.org/10.1200/jco.2009.25.3641.
Повний текст джерелаBrosinsky, Paulin, Julia Bornbaum, Björn Warga, Lisa Schulz, Klaus-Dieter Schlüter, Alessandra Ghigo, Emilio Hirsch, Rainer Schulz, Gerhild Euler та Jacqueline Heger. "PI3K as Mediator of Apoptosis and Contractile Dysfunction in TGFβ1-Stimulated Cardiomyocytes". Biology 10, № 7 (16 липня 2021): 670. http://dx.doi.org/10.3390/biology10070670.
Повний текст джерелаMeadows, Sarah, Sorensen Rick, Yahiaoui Anella, Jia Liu, Li Li, Peng Yue, Christophe Queva, and Stacey Tannheimer. "Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib." Blood 126, no. 23 (December 3, 2015): 3707. http://dx.doi.org/10.1182/blood.v126.23.3707.3707.
Повний текст джерелаBeck, Patrick, Kasen Reed Hutchings, Eileen Xu, Erin McDaid, Vincent Bui, Chinkal Patel, Jaime Solis, et al. "PIK3CB as a potential target to regulate chemosensitivity in glioblastoma." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e14051-e14051. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14051.
Повний текст джерелаMolins, Joaquim Bellmunt, Lillian Werner, Marta Guix, Elizabeth Ann Guancial, Fabio Augusto Barros Schutz, Robert O'Brien, Edward C. Stack, et al. "PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?" Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 4582. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4582.
Повний текст джерелаCao, Biyin, Jingyu Zhu, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Zubin Zhang, et al. "A Novel PI3K Inhibitor Identified By a High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 4722. http://dx.doi.org/10.1182/blood.v124.21.4722.4722.
Повний текст джерелаLobo, Vítor, Ashly Rocha, Tarsila G. Castro, and Maria Alice Carvalho. "Synthesis of Novel 2,9-Disubstituted-6-morpholino Purine Derivatives Assisted by Virtual Screening and Modelling of Class I PI3K Isoforms." Polymers 15, no. 7 (March 29, 2023): 1703. http://dx.doi.org/10.3390/polym15071703.
Повний текст джерелаGuenther, Andreas, Renate Burger, Wolfram Klapper, Matthias Staudinger, and Martin Gramatzki. "Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival." Blood 122, no. 21 (November 15, 2013): 5364. http://dx.doi.org/10.1182/blood.v122.21.5364.5364.
Повний текст джерелаJeong, Jae Seok, Jong Seung Kim, So Ri Kim, and Yong Chul Lee. "Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management." International Journal of Molecular Sciences 20, no. 14 (July 18, 2019): 3525. http://dx.doi.org/10.3390/ijms20143525.
Повний текст джерелаChen, Yingwei, Bao-Can Wang, and Yongtao Xiao. "PI3K: A potential therapeutic target for cancer." Journal of Cellular Physiology 227, no. 7 (March 20, 2012): 2818–21. http://dx.doi.org/10.1002/jcp.23038.
Повний текст джерелаRathinaswamy, Manoj K., Udit Dalwadi, Kaelin D. Fleming, Carson Adams, Jordan T. B. Stariha, Els Pardon, Minkyung Baek та ін. "Structure of the phosphoinositide 3-kinase (PI3K) p110γ-p101 complex reveals molecular mechanism of GPCR activation". Science Advances 7, № 35 (серпень 2021): eabj4282. http://dx.doi.org/10.1126/sciadv.abj4282.
Повний текст джерелаSmith, Stephen F., Shannon E. Collins, and Pascale G. Charest. "Ras, PI3K and mTORC2 – three's a crowd?" Journal of Cell Science 133, no. 19 (October 1, 2020): jcs234930. http://dx.doi.org/10.1242/jcs.234930.
Повний текст джерелаGong, Grace Q., Jackie D. Kendall, James M. J. Dickson, Gordon W. Rewcastle, Christina M. Buchanan, William A. Denny, Peter R. Shepherd та Jack U. Flanagan. "Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity". Biochemical Journal 474, № 13 (26 червня 2017): 2261–76. http://dx.doi.org/10.1042/bcj20161098.
Повний текст джерелаNarayanankutty, Arunaksharan. "PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence." Current Drug Targets 20, no. 12 (August 22, 2019): 1217–26. http://dx.doi.org/10.2174/1389450120666190618123846.
Повний текст джерелаKang, Byung Woog, and Ian Chau. "Molecular target: pan-AKT in gastric cancer." ESMO Open 5, no. 5 (September 2020): e000728. http://dx.doi.org/10.1136/esmoopen-2020-000728.
Повний текст джерелаBheemanaboina, Rammohan R. Y. "Isoform-Selective PI3K Inhibitors for Various Diseases." Current Topics in Medicinal Chemistry 20, no. 12 (June 1, 2020): 1074–92. http://dx.doi.org/10.2174/1568026620666200106141717.
Повний текст джерелаUche, Uzodinma U., Ann R. Piccirillo, Shunsuke Kataoka, Stephanie J. Grebinoski, Louise M. D’Cruz, and Lawrence P. Kane. "PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt." Journal of Experimental Medicine 215, no. 12 (November 14, 2018): 3165–79. http://dx.doi.org/10.1084/jem.20172018.
Повний текст джерелаGoncalves, Marcus D., and Azeez Farooki. "Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia." Integrative Cancer Therapies 21 (January 2022): 153473542110731. http://dx.doi.org/10.1177/15347354211073163.
Повний текст джерелаThillai, Kiruthikah, Debashis Sarker, and Claire Wells. "PAK4 as a potential therapeutic target in pancreatic ductal adenocarcinoma (PDAC)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e23139-e23139. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23139.
Повний текст джерелаSmith, Greg C., Wee Kiat Ong, Gordon W. Rewcastle, Jackie D. Kendall, Weiping Han, and Peter R. Shepherd. "Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo." Biochemical Journal 442, no. 1 (January 27, 2012): 161–69. http://dx.doi.org/10.1042/bj20111913.
Повний текст джерелаJia, Wen-Qing, Xiao-Yan Feng, Ya-Ya Liu, Zhen-Zhen Han, Zhi Jing, Wei-Ren Xu та Xian-Chao Cheng. "Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the p110δ/γ Crystal Structure". Letters in Drug Design & Discovery 17, № 6 (29 червня 2020): 772–86. http://dx.doi.org/10.2174/1570180816666190730163431.
Повний текст джерелаZhang, Xuewei, Masumi Ishibashi, Kazuyuki Kitatani, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Muneaki Shimada, and Nobuo Yaegashi. "Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer." Cancers 12, no. 6 (June 26, 2020): 1705. http://dx.doi.org/10.3390/cancers12061705.
Повний текст джерелаRezende, Denise C., Lorena Zaida Pacheco, Luis Arthur F. Pelloso, Maria L. Chauffaille, Marçal C. A. Silva, Elisa Kimura, Rafael L. Casaes-Rodrigues, Helena Segreto, Mihoko Yamamoto, and Daniella Marcia Maranhao Bahia Kerbauy. "PI3K/AKT Pathway as a Potential Therapeutic Target In Myelodysplastic Syndrome." Blood 116, no. 21 (November 19, 2010): 1871. http://dx.doi.org/10.1182/blood.v116.21.1871.1871.
Повний текст джерелаBlunt, Matthew D., Matthew J. Carter, Marta Larrayoz, Maria Montserrat Aguilar, Sarah Murphy, Mark Reynolds, Thomas Tipton, et al. "The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ-TCL1 Mouse Model." Blood 124, no. 21 (December 6, 2014): 832. http://dx.doi.org/10.1182/blood.v124.21.832.832.
Повний текст джерелаChen, Yu-Chen Enya, Melinda Lea Burgess, Antje Blumenthal, Sally Mapp, Peter Mollee, Devinder Gill, and Nicholas Andrew Saunders. "Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta." Blood 132, Supplement 1 (November 29, 2018): 3128. http://dx.doi.org/10.1182/blood-2018-99-109719.
Повний текст джерелаBosch, Ana, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao, et al. "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer." Science Translational Medicine 7, no. 283 (April 15, 2015): 283ra51. http://dx.doi.org/10.1126/scitranslmed.aaa4442.
Повний текст джерелаGiulino Roth, Lisa, Herman van Besien, Anna Rodina, Tony Taldone, Hediye Erdjument-Bromage, Matthew J. Barth, Gabriela Chiosis, and Ethel Cesarman. "Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma." Blood 126, no. 23 (December 3, 2015): 592. http://dx.doi.org/10.1182/blood.v126.23.592.592.
Повний текст джерелаPopova, Nadezhda V., and Manfred Jücker. "The Role of mTOR Signaling as a Therapeutic Target in Cancer." International Journal of Molecular Sciences 22, no. 4 (February 9, 2021): 1743. http://dx.doi.org/10.3390/ijms22041743.
Повний текст джерелаDent, Paul, Steven Grant, Paul B. Fisher, and David T. Curiel. "PI3K: a rational target for ovarian cancer therapy?" Cancer Biology & Therapy 8, no. 1 (January 2009): 27–30. http://dx.doi.org/10.4161/cbt.8.1.7365.
Повний текст джерелаMalik, Nazma, Thomas Macartney, Annika Hornberger, Karen E. Anderson, Hannah Tovell, Alan R. Prescott, and Dario R. Alessi. "Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks." Biochemical Journal 475, no. 1 (January 2, 2018): 117–35. http://dx.doi.org/10.1042/bcj20170650.
Повний текст джерелаMabrouk, Mohammed El, Quy N. Diep, Karim Benkirane, Rhian M. Touyz, and Ernesto L. Schiffrin. "SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension." American Journal of Physiology-Heart and Circulatory Physiology 286, no. 5 (May 2004): H1954—H1962. http://dx.doi.org/10.1152/ajpheart.00134.2003.
Повний текст джерелаYan, Zhao, Guangmei Liu, Yang Yang, Ling Chen, Ying Shang, and Qian Hong. "Identifying mechanisms of Epimedii Folium against Alzheimer’s disease via a network pharmacology approach Epimedii Folium treats Alzheimer’s disease via PI3K-AKT." European Journal of Inflammation 19 (January 2021): 205873922110414. http://dx.doi.org/10.1177/20587392211041435.
Повний текст джерелаGao, Haotian, Zaolin Li, Kai Wang, Yuhan Zhang, Tong Wang, Fang Wang, and Youjun Xu. "Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors." Pharmaceuticals 16, no. 3 (March 20, 2023): 461. http://dx.doi.org/10.3390/ph16030461.
Повний текст джерелаZapevalova, Maria V., Ekaterina S. Shchegravina, Irina P. Fonareva, Diana I. Salnikova, Danila V. Sorokin, Alexander M. Scherbakov, Alexander A. Maleev, et al. "Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway." International Journal of Molecular Sciences 23, no. 18 (September 17, 2022): 10854. http://dx.doi.org/10.3390/ijms231810854.
Повний текст джерелаWang, Xiaohui, Lin Zhou, Tao Zhang, Hui Chen, Xinhao Song, and Feng Wang. "Effect and Mechanism of Schizandrin A in the Treatment of Liver Cancer Using Network Pharmacology, Molecular Docking, and Target Validation." Natural Product Communications 18, no. 5 (May 2023): 1934578X2311769. http://dx.doi.org/10.1177/1934578x231176916.
Повний текст джерелаLi, Jun-min, Zi-zhen Xu, Ai-hua Wang, and Jiong Hu. "Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab." Blood 114, no. 22 (November 20, 2009): 1934. http://dx.doi.org/10.1182/blood.v114.22.1934.1934.
Повний текст джерелаCaforio, Matteo, Emmanuel de Billy, Biagio De Angelis, Stefano Iacovelli, Concetta Quintarelli, Valeria Paganelli, and Valentina Folgiero. "PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches." Cancers 13, no. 16 (August 11, 2021): 4040. http://dx.doi.org/10.3390/cancers13164040.
Повний текст джерелаKnight, Z. A., and K. M. Shokat. "Chemically targeting the PI3K family." Biochemical Society Transactions 35, no. 2 (March 20, 2007): 245–49. http://dx.doi.org/10.1042/bst0350245.
Повний текст джерелаZuo, Ximeng, Xiaoguang Shi, Xuedan Zhang, Zhenzhou Chen, Zhenrui Yang, Xiaojuan Pan, Rui Lai, and Ze Zhao. "Postoperative Ileus with the Topical Application of Tongfu Decoction Based on Network Pharmacology and Experimental Validation." Evidence-Based Complementary and Alternative Medicine 2022 (March 28, 2022): 1–12. http://dx.doi.org/10.1155/2022/2347419.
Повний текст джерела